A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in Subjects with Relapsing Multiple Sclerosis
What was tested
Treatment tested
- NA
Loading reviews and guidelines…
History
- In scope changed from true to false
Started
Aug 2004
Assembled by software from public sources.